araag2/HINT huggingface dataset:
Clinical trial NCT00601796 (phase 2, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: cyclophosphamide, all-trans retinoic acid (atra)
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed metastatic adenocarcinoma of the lung

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, or 1

          -  No radiation therapy within 2 weeks of first vaccine administration

          -  No chemotherapy within 4 weeks of first vaccine administration

          -  No steroid therapy within 4 weeks of first vaccine administration

          -  Patient's written informed consent

          -  Adequate organ function (measured within a week of beginning treatment)

          -  Patients will be tested for human leukocyte antigen A0201 (HLA-A0201) as determined by
             flow cytometry followed by molecular analysis of a peripheral blood specimen, however
             this result will not be an inclusion criterion.

          -  Measurable metastatic tumor as defined by standard Response Evaluation Criteria In
             Solid Tumors (RECIST) criteria. Lesions must be accurately measured in at least one
             dimension with the longest diameter greater than or equal 20mm. With spiral computer
             tomography (CT) scan, lesion must be greater than or equal to 10 mm at least one
             dimension.

          -  Patient's must have received, and completed first line chemotherapy.

        Exclusion Criteria:

          -  Symptomatic brain metastasis

          -  Any acute medical problems requiring active intervention

          -  Current corticosteroid (other than replacement doses in patients who are hypoadrenal)
             or other immunosuppressive therapy

          -  Any other pre-existing immunodeficiency condition (including known HIV infection)

          -  Pregnant or lactating women -- Patients in reproductive age must agree to use
             contraceptive methods for the duration of the study (*A pregnancy test will be
             obtained before treatment).

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 2, 3 or 4
Clinical trial NCT01027260 (phase 2, status: completed)
Conditions: irritable bowel syndrome
ICD codes: K58.2, K58.8, K58.0, K58.1, K58.9
Drugs: itopride hci 50 mg, itopride hci 100 mg, placebo
SMILES: COC1=CC=C(C=C1OC)C(=O)NCC1=CC=C(OCCN(C)C)C=C1, COC1=CC=C(C=C1OC)C(=O)NCC1=CC=C(OCCN(C)C)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female patient fulfilling the Rome III criteria for IBS-C

          2. Signed informed consent at screening visit

        Exclusion Criteria:

          1. Patients having significant diarrhea at least 25% of the time during the past 3 months

          2. Patients having alarm symptoms or signs

          3. Chronic diarrhea

          4. History of gastrointestinal haemorrhage, mechanical obstruction or perforation

          5. Patient with clinically relevant ECG abnormalities (prolonged QT interval)

          6. Active psychiatric disorder that would interfere with the study objectives

          7. Health conditions (e.g. age related impairment of cognitive functions) that would
             interfere with the study objectives or might impair the compliance of the patient

          8. Severe hepatic, renal, cardiac, metabolic, haematological or malignant diseases
             (including prolactin dependent tumours) or clinically relevant deviations in
             laboratory values (AST/ALT greater than twice the upper limit of normal, serum
             creatinine * 2 mg/dl [177 µmol/l] according to the medical judgement of the
             investigator

          9. Patient with hypokalemia (serum potassium < 3.5 mmol/l).

         10. History of any known hypersensitivity to the ingredients of the investigational drug

         11. Pregnancy or lactation

         12. Women with childbearing potential who do not apply a medically accepted method of
             contraception.
Clinical trial NCT00207740 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: cnto148, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Physician diagnosis of asthma for greater than or equal to 3 years and a diagnosis of
             severe persistent asthma forgreater than or equal to 1 year prior to screening

          -  Continuous treatment with high dose Inhaled corticosteroids (ICS) and long acting
             beta-agonist for at least 3 months prior to screening

          -  Have evidence of at least 1 of the following in the 5 years prior to screening or
             during screening, reversible airway obstruction greater than or equal to 12 percentage
             change in forced expiratory volume in 1 second (FEV1) postbronchodilator; Diurnal
             variation in peak expiratory flow rate (PEFR) greater than or equal to 30 percentage
             change) and airway hyperresponsiveness

          -  Estimated frequency of symptoms on more than one-third of days for at least 3 months
             prior to screening (eg, wheezing, breathlessness, chest tightness, cough, nocturnal
             awakening) despite treatment with high dose ICS and long-acting β2-agonist (LABA),
             with or without continuous oral corticosteroids

          -  Score of greater than or equal to 2 points on the asthma control questionnaire at
             screening.

        Exclusion Criteria:

          -  Diagnosis of chronic obstructive pulmoanry disease (COPD), cystic fibrosis, or other
             significant respiratory disorder

          -  Worsening of asthma symptoms that required treatment with an addition or increase in
             oral corticosteroids dose (steroid burst) in the 4-week period prior to the screening
             visit

          -  Life-threatening asthma attack requiring cardiopulmonary support (eg, intubation) in
             the 6-month period prior to screening

          -  Have ever used alkylating agents (eg, chlorambucil or cyclophosphamide)

          -  Concomitant diagnosis or any history of congestive heart failure (CHF), including
             medically controlled CHF.
Clinical trial NCT00640458 (phase 2, status: completed)
Conditions: female sexual arousal disorder
ICD codes: F52.22
Drugs: sildenafil 100 mg, placebo
SMILES: CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Pre-menopausal women aged 18-45 with a primary diagnosis of Female Sexual Arousal
             Disorder for at least 6 months prior to entering the study. The FSAD could have been
             associated with female orgasmic disorder (FOD) and/or superficial or introital
             dyspareunia.

        Exclusion Criteria:

          -  Subjects with hypoactive sexual desire disorder.

          -  Subjects not using an acceptable mean of contraception for the duration of the study.

          -  Subjects who were prescribed and/or taking medication which were contraindicated or
             cautioned with concomitant intake of sildenafil.
Clinical trial NCT01345656 (phase 2, status: completed)
Conditions: heart failure
ICD codes: I50.814, I09.81, I50.82, I50.89, I50.9, T86.22, I11.0
Drugs: bay94-8862, bay94-8862, bay94-8862, bay94-8862, placebo, spironolactone
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC1=CC(C)=C(C=C1)C(=O)OCC1=CC=C(C=C1)[C@@H](CN)C(=O)NC1=CC=C2C=NC=CC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Men aged 18 years and older or postmenopausal women aged 55 years and older or women
             aged 18 years and older without childbearing potential based on surgical treatment
             such as bilateral tubal ligation, bilateral ovarectomy, or hysterectomy

          -  Clinical diagnosis of CHF (chronic heart failure), either ischemic or non-ischemic,
             NYHA (New York Heart Association) class II - III, treated with evidenced-based therapy
             for CHF, e.g. beta-blockers and ACE (angiotensin-converting enzyme) inhibitors or ARB
             (angiotensin receptor blocker) as well as diuretics, unless contraindicated or not
             tolerated

          -  Known kidney damage for >/= 3 months, as defined by structural or functional
             abnormalities of the kidney, and

               -  Part A: 60 mL/min/1.73 m2 </= eGFR (estimated Glomerular Filtration Rate) < 90
                  mL/min/1.73 m2 (MDRD, Modification of Diet in Renal Disease) at the screening
                  visit

               -  Part B: 30 mL/min/1.73 m2 </= eGFR <= 60 mL/min/1.73 m2 (MDRD) at the screening
                  visit

          -  Serum potassium </= 4.8 mmol/L at the screening visit

          -  Systolic blood pressure >/= 90 mmHg without signs or symptoms of hypotension at the
             screening visit

        Exclusion Criteria:

          -  Known hypersensitivity to the study drug (active substance or excipients) or
             spironolactone and respective excipients (Part B only)

          -  Subjects with anuria, acute renal failure, or Addison's disease

          -  Acute coronary syndrome or unstable coronary artery disease within 30 days prior to
             randomization

          -  Valvular heart disease requiring surgical intervention during the course of the study

          -  History of hospitalization for hyperkalemia or acute renal failure induced by previous
             aldosterone antagonist treatment
Clinical trial NCT01222533 (phase 2, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: tiotropium medium, tiotropium low, tiotropium high, tiotropium 18mcg, tiotropium placebo
SMILES: [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1
Eligibility criteria:

        Inclusion criteria:

          1. All patient must sign an informed consent consistent with IInternational Conference on
             Harmonisation- Good Clinical Practice (ICH-GCP) guidelines and local legislation prior
             to any study-related procedures, including medication washout and restrictions.

          2. Relatively stable, moderate to very severe Chronic Obstructive Pulmonary Disease
             (COPD)

          3. Current or ex-smokers (smoking history of at least 10 pack years)

          4. Able to perform lung function tests

          5. Able to use study inhalers

        Exclusion criteria:

          1. Significant diseases other than COPD

          2. Recent myocardial infarction, unstable or life-threatening cardiac arrhythmia,
             hospitalisation for cardiac failure.

          3. Malignancy requiring resection, radiation therapy or chemotherapy within the last 5
             years

          4. History of asthma, life-threatening pulmonary obstruction, cystic fibrosis or
             clinically evident bronchiectasis 5 Active tuberculosis

        6. History of alcohol or drug abuse 7. Pulmonary resection 8. Recent completion of a
        pulmonary rehabilitation program or current participation which will not be continued 9.
        Daytime oxygen therapy for more than 1 hour per day. 10. Use of other investigational
        drugs, restrictions on the use of some respiratory medications during the study period.

        11. Current participation in another clinical trial 12. Pregnant or nursing women 13. Women
        of childbearing potential not using a highly effective method of contraception (e.g:
        implants, injectable, oral contraceptives)
Clinical trial NCT01542255 (phase 2, status: terminated)
Conditions: metastatic melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: vinblastine, cyclophosphamide, dacarbazine
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, N1C=CN=C1
Reason stopped: 
    low accrual not allowing to support statistical endpoints
  
Eligibility criteria:

        -  Metastatic melanoma with measurable disease

          -  Patients must be at least 4 weeks from their last immunotherapy, radiation, surgery or
             chemotherapy (6 weeks for nitrosoureas) and recovered from all ill

          -  Karnofsky Performance Status ≥60%

          -  Life expectancy ≥ twelve weeks

          -  Adequate end organ function

          -  Women should not be lactating and, if of childbearing age, have a negative pregnancy
             test within two weeks of entry to the study.

          -  Appropriate Contraception in both sexes

          -  The patient must be competent and signed informed consent.

        EXCLUSION CRITERIA

          -  Concomitant second malignancy except for non-melanoma skin cancer, and non-invasive
             cancer such as cervical CIS, superficial bladder cancer without local recurrence,
             breast CIS.

          -  In patients with a prior history of invasive malignancy, less than five years in
             complete remission.

          -  Have evidence of significant co-morbid illness such as uncontrolled diabetes -
             Uncontrolled brain metastasis: Patients with brain metastasis most have been treated
             with brain radiation therapy or surgery and remain clinically stable for a minimum of
             4 weeks.
Clinical trial NCT00394563 (phase 2, status: completed)
Conditions: osteoarthritis
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: rn624 (pf-04383119), rn624 (pf-04383119), rn624 (pf-04383119), rn624 (pf-04383119), rn624 (pf-04383119), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        Male or non-pregnant female aged 40-75 with chronic moderate to severe knee pain due to OA
        (scoring 50 out of 100 on a visual analog scale on knee pain).

        Subjects must meet one of the following: unwilling to take non-opiate pain medications, or
        for whom non-opiate pain medications have failed, or are candidates for or seeking invasive
        interventions such as intraarticular injections, knee arthroplasty, or total knee surgery

        Exclusion Criteria:

        History or symptoms of autoimmune disorders, cancer within the last 5 years except for
        cutaneous basal cell or squamous cell cancer resolved by excision, allergic reaction to
        monoclonal antibodies or IgG-fusion proteins, Hepatitis B, C or HIV, drug abuse,
        fibromyalgia, clinically significant cardiac disease, diabetes mellitus requiring oral
        treatment or insulin, clinically significant neurological disease or clinically significant
        psychiatric disorders
Clinical trial NCT00480090 (phase 2, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: cytarabine
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Biopsy-proven prostate cancer or clinical picture consistent with metastatic prostate
             cancer with high level of serum PSA (> 20ng/ml)

          -  At least 4 weeks after docetaxel treatment and have at least 2 consecutive rising PSAs
             measured at least 2 weeks apart

          -  Progression on or intolerance of docetaxel chemotherapy

          -  ECOG performance status ≤ 2

          -  Adequate organ and marrow function

        Exclusion Criteria:

          -  Prior treatment with cytarabine

          -  Receiving any other investigational or anticancer agents

          -  Uncontrolled intercurrent illness

          -  Active malignancy at any other site excluding squamous cell or basal cell carcinomas
             of the skin

          -  Radiotherapy within the past 4 weeks
Clinical trial NCT00387907 (phase 2, status: completed)
Conditions: advanced breast cancer, breast cancer, metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: larotaxel (xrp9881), trastuzumab
SMILES: CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@H]3[C@]4(C[C@H]4C[C@H]4OC[C@@]34OC(C)=O)C1=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of breast cancer

          -  Evidence that cancer has spread beyond its original location or has come back and
             cannot be removed by surgery

          -  No more than one prior treatment for advanced disease

          -  Her2 positive status

          -  Adequate liver and kidney function

          -  No remaining severe harmful effects to prior treatments

        Exclusion Criteria:

          -  Certain heart condition

          -  Pregnant Women

          -  History of another cancer except some skin cancers and cervical cancer

          -  Taking other treatments for your cancer at the time you enter the trial
Clinical trial NCT00201825 (phase 2, status: completed)
Conditions: lung cancer, non-small-cell lung carcinoma
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, D02.20, D02.21, D02.22
Drugs: capecitabine, docetaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Must have advanced NSCLC

          -  No prior chemotherapy

          -  Eastern Cooperative Oncology Group(ECOG)Performance Status:0 or 1

          -  Must have measurable disease (RECIST criteria)

          -  life expectancy of at least 12 weeks

          -  adequate organ function including

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Psychiatric disorders that would interfere w/consent or follow-up

          -  Patients with uncontrolled diabetes mellitus, defined as random blood sugar >
             250mg/dL.
Clinical trial NCT01766466 (phase 2, status: completed)
Conditions: coronary artery disease
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: cangrelor, ticagrelor
SMILES: CSCCNC1=C2N=CN([C@@H]3O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC(SCCC(F)(F)F)=N1, [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  greater than / equal to 18 and less than 75 years of age

               1. Previous myocardial infarction defined by admission to the hospital with
                  elevation of markers of injury or the presence of pathologic q waves on at least
                  2 contiguous electrocardiogram (ECG) leads.

                  OR

               2. Previous revascularization by percutaneous coronary intervention (PCI) or
                  coronary artery bypass graft (CABG) surgery.

                  AND

               3. Treatment with aspirin (ASA) 81 mg daily.

                  Exclusion Criteria:
Clinical trial NCT00621868 (phase 2, status: completed)
Conditions: diabetes mellitus
ICD codes: P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9
Drugs: ipragliflozin, placebo
SMILES: OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(F)C(CC2=CC3=CC=CC=C3S2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Established diagnosis of type 2 diabetes mellitus

          -  Fasting serum C-peptide level > 0.6 ng/mL

          -  HbA1c between 7.0 and 10.0%

          -  Body Mass Index between 20 and 45 kg/m2

        Exclusion Criteria:

          -  Serum creatinine > upper limit of normal

          -  Proteinuria (albumin/creatinine ratio > 300 mg/g)

          -  Dysuria and/or urinary tract infection

          -  Significant renal, hepatic or cardiovascular diseases

          -  Ketosis

          -  Hypertension

          -  Severe gastrointestinal diseases
Clinical trial NCT01105377 (phase 2, status: completed)
Conditions: recurrent colon cancer, recurrent rectal cancer, stage iv colon cancer, stage iv rectal cancer
ICD codes: C18.2, C18.4, C18.6, C18.7, C18.9, D12.2, D12.3, G47.13, J01.41, K11.22, K12.0, N96, F33.8, G03.2
Drugs: entinostat, azacitidine
SMILES: NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed metastatic colorectal cancer

          -  Measurable disease

          -  Patient has failed ≥ 2 prior chemotherapy regimens

          -  Not a candidate for curative resection

          -  No CNS metastases within ≤ 2 years

               -  Treatment for brain metastasis and whole brain disease that has remained stable
                  for > 3 months allowed

               -  Patients who have not been treated with steroid therapy may be allowed

          -  ECOG performance status 0-1

          -  Life expectancy ≥ 12 weeks

          -  Leukocytes ≥ 3,000/mm^3

          -  ANC ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  AST and ALT ≤ 2.5 times ULN

          -  Creatinine normal OR creatinine clearance ≥ 60 mL/min

          -  Negative pregnancy test

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  Sensory neuropathy ≤ grade 2 allowed

          -  Willing to provide tissue and blood samples

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biologic composition to entinostat, azacitidine, mannitol, or other agents used in the
             study

          -  No uncontrolled intercurrent illness including, but not limited to, any of the
             following:

               -  Ongoing or active infection

               -  NYHA class II-IV symptomatic congestive heart failure

               -  Unstable angina pectoris

               -  Cardiac arrhythmia

               -  Psychiatric illness and/or social situations that would limit compliance with
                  study requirements

          -  No history of severe bleeding without thrombocytopenia

          -  No concurrent radiotherapy including palliative treatment

          -  Toxicities from prior therapy have resolved to ≤ grade 1

          -  More than 4 weeks since prior chemotherapy (> 6 weeks for nitrosoureas or mitomycin C)

          -  More than 4 weeks since prior major surgical procedure

          -  No prior histone deacetylase inhibitors (including valproic acid) or demethylating
             agents

          -  No concurrent investigational agents

          -  No concurrent combination antiretroviral therapy in HIV-positive patients

          -  No concurrent investigational or commercial anticancer agents or therapies